Abstract
A multifunctional dendritic nanodevice containing folate (FA) as the targeting molecule and daunorubicin (DNR) as the chemotherapeutic drug has been designed and synthesized. The primary amino groups on the surface of the generation 5 poly(amidoamine) dendrimer (G5 dendrimer) were acetylated partially. FA and DNR were conjugated to the remaining primary amino groups on the G5 dendrimer through amide and ester linkage, respectively, to generate the difunctional dendritic device. The synthetic approach of G5 PAMAM dendrimer containing daunorubicin and folic acid would be useful for targeting the overexpressed membrance-associated folate receptors of KB human carcinoma cell line and discreating them effectively.
Similar content being viewed by others
References
Agarwal, A., Saraf, S., Asthana, A., Gupta, U., Gajbhiye, V., and Jain, N. K., Ligand based dendritic systems for tumor targeting. Int. J. Pharm., 350, 3–13 (2008).
Bosman, A. W., Janssen, H. M., and Meijer, E. W., About dendrimers: Structure, physical properties, and applications. Chem. Rev., 99, 1665–1688 (1999).
Esfand, R. and Tomalia, D. A., Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today, 6, 427–436 (2001).
Huang, B., Desai, A., Zong, H., Tang, S., Leroueil, P., and Baker Jr., J. R., Copper-free click conjugation of methotrexate to a PAMAM dendrimer platform. Tetrahedron Lett., 52, 1411–1414 (2011).
Kono, K., Liu, M., and Frechet, J. M. J., Design of dendritic macromolecules containing folate or methotrexate residues. Bioconjugate Chem., 10, 1115–1121 (1999).
Majoros, I. J., Keszler, B., and Woehler, S., Acetylation of poly (amidoamine) dendrimers. Macromolecules, 36, 5526–5529 (2003).
Majoros, I. J., Thomas, T. P., Methta, C. B., and Baker Jr., J. R., Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J. Med. Chem., 48, 5892–5899 (2005).
Majoros, I. J., Myc, A., Thomas, T., Mehta, C. B., and Baker Jr., J. R., PAMAM dendrimer-based multifunctional conjugate for cancer therapy: Synthesis, characterization, and functionality. Biomacromolecules, 7, 572–579 (2006).
Medina, S. H. and El-Sayed, M. E. H., Dendrimers as carriers for delivery of chemotherapeutic agents. Chem. Rev., 109, 3141–3157 (2009).
Myc, A., Majoros, I. J., Thomas, T. P., and Baker Jr, J. R., Dendrimer-based targeted delivery of an apoptotic sensor in cancer cells. Biomacromolecules, 8, 13–18 (2007).
Singh, P., Gupta, U., Asthana, A., and Jain, N, K., Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjugate Chem., 19, 2239–2252 (2008).
Sudimack, J. and Lee, R. J., Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev., 41, 147–162 (2000).
Svenson, S. and Tomalia, D. A., Dendrimers in biomedical applications-reflections on the field. Adv. Drug Deliv. Rev., 57, 2106–2129 (2005).
Tekade, R. K., Kumar, P. V., and Jain, N. K., Dendrimers in oncology: An expanding horizon. Chem. Rev., 109, 49–87 (2009).
Thomas, T. P., Majoros, I. J., Kotlyar, A., Kukowska-Latallo, J. F., Bielinska, A., Myc, A., and Baker Jr., J. R., Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J. Med. Chem., 48, 3729–3735 (2005).
Weiss, R. B., The anthracyclins: Will we ever find a better doxorubicin? Semin. Oncol., 19, 670–686 (1992).
Zhu, S., Hong, M., and Tang, G., Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: The effects of PEGylation degree and drug conjugation style. Biomaterials, 31, 1360–1371 (2010).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Yue, Y., Eun, J.S., Lee, MK. et al. Synthesis and characterization of G5 PAMAM dendrimer containing daunorubicin for targeting cancer cells. Arch. Pharm. Res. 35, 343–349 (2012). https://doi.org/10.1007/s12272-012-0215-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-012-0215-7